TNF

INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024

Retrieved on: 
星期二, 二月 6, 2024
TNF, Science, Axon, MD, MCI, Neurology, CFS, Acquisition, White matter, University of Florida, Doctor of Philosophy, University, Webcast, NFL, Pharmaceutical industry

Boca Raton, Florida, Feb. 06, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s disease (AD) with XProTM (XPro1595; pegipanermin), a dominant-negative inhibitor of soluble TNF, announces its management will be participating in Baird’s Biotech Discovery Series webcast on Tuesday, February 13, 2024 at 10:30AM EST.

Key Points: 
  • Boca Raton, Florida, Feb. 06, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s disease (AD) with XProTM (XPro1595; pegipanermin), a dominant-negative inhibitor of soluble TNF, announces its management will be participating in Baird’s Biotech Discovery Series webcast on Tuesday, February 13, 2024 at 10:30AM EST.
  • The speakers will cover two key topics – first, they will provide an update on the unique features of the Company’s  ongoing blinded, randomized, placebo-controlled Phase II trial for Early Alzheimer's disease (MCI/Mild AD).
  • Baird’s Biotech Discovery Series, which launched in early 2022, is an opportunity for investors to hear directly from interesting and innovative public and private biotech companies in a fireside chat format.
  • We invite key members of management and frequently ask related third parties to join the discussion to learn why they are excited about the science and opportunity for these emerging biotech leaders.

INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program

Retrieved on: 
星期二, 一月 30, 2024
TNF, Neuroinflammation, Patient, FDA, Phase

BOCA RATON, Florida, Jan. 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB)  (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s disease (AD) with XProTM (XPro1595; pegipanermin), a dominant-negative inhibitor of soluble TNF, received correspondence from the FDA confirming that the full clinical hold on the Company’s AD clinical trial program has been lifted. The Phase II trial is on track to enroll the last patient mid-2024. Top line data is expected approximately six months after the last patient is enrolled.

Key Points: 
  • The Phase II clinical trial in patients with Alzheimer’s disease with neuroinflammation is on track to complete enrollment mid-2024 with top line data expected approximately six months after the final patient is enrolled.
  • BOCA RATON, Florida, Jan. 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB)  (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s disease (AD) with XProTM (XPro1595; pegipanermin), a dominant-negative inhibitor of soluble TNF, received correspondence from the FDA confirming that the full clinical hold on the Company’s AD clinical trial program has been lifted.
  • The Phase II trial is on track to enroll the last patient mid-2024.
  • “We are pleased with the FDA’s response and will continue to work closely with the agency in anticipation of our Phase III AD program,” said RJ Tesi, CEO of INmune Bio.

Orphan designation: chimeric human-murine IgG1 kappa monoclonal antibody against TNF alfa Treatment of sarcoidosis, 25/07/2023 Positive

Retrieved on: 
星期日, 二月 4, 2024
TNF, Sarcoidosis, Immunoglobulin G, COMP, IRIS, EMA, European Commission, Patient, Committee, Pharmaceutical industry

Key facts

Key Points: 
  • Key facts
    - Active substance
    - chimeric human-murine IgG1 kappa monoclonal antibody against TNF alfa
    - Intended use
    - Treatment of sarcoidosis
    - Orphan designation status
    - Positive
    - EU designation number
    - EU/3/23/2809
    - Date of designation
    - Sponsor
    FGK Representative Service GmbH
    Patients' organisations
    For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
    European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • EU register of orphan medicines
    The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:
    EMA list of opinions on orphan medicinal product designation
    EMA publishes information on orphan medicinal product designation adopted by the Committee for Orphan Medicinal Products (COMP) on the IRIS online platform:

Changes Afoot for the Treatment of Psoriatic Arthritis with Marked Gains in Preference and Utilization of IL-17 Inhibitors

Retrieved on: 
星期一, 一月 22, 2024
Need for Speed, Psoriatic arthritis, Patient, US FDA, RealTime, TNF, Joint, Rheumatology, Mechanism of action, HCP, Skin, Secukinumab, MOA, Physician, Pharmaceutical industry

However, recent years have witnessed a transformative shift in both the US and EU markets, as rheumatologists increasingly favor alternative mechanisms, notably IL-17 inhibitors.

Key Points: 
  • However, recent years have witnessed a transformative shift in both the US and EU markets, as rheumatologists increasingly favor alternative mechanisms, notably IL-17 inhibitors.
  • In contrast, within that timeframe, rheumatologists saw a preference for IL-17s more than double, indicating a noteworthy transformation in treatment preferences.
  • Over half of rheumatologists cite efficacy as their primary motive for favoring IL-17 inhibitors in PsA treatment, regularly underscoring the class’s success in treating both skin and joint manifestations.
  • As the treatment landscape for PsA undergoes dynamic changes, staying ahead of these shifting trends becomes essential for effective patient management and optimal treatment outcomes.

Oculis to Host In-Person & Virtual R&D Day in New York on February 28, 2024

Retrieved on: 
星期一, 一月 22, 2024
Dexamethasone, Patient, Telecanthus, TNF, University, Diabetic retinopathy, OCS, Inflammation, University of Nevada, Reno, DED, Retina, DME

Please click here to attend the event either in-person or virtually.

Key Points: 
  • Please click here to attend the event either in-person or virtually.
  • Location details for in-person attendance will be provided upon registration.
  • (Director, Oculis’ Board) and Riad Sherif, M.D.
  • In addition, management will provide a brief 2023 review and business outlook for 2024.

THE NEWS FORUM airs the action adventure documentary ADAPTATION – The World’s first downhill mountain bike race series to include an adaptive mountain bike (aMTB) category

Retrieved on: 
星期五, 一月 19, 2024
Family, TNF, The News Forum, Athlete, Friends, Adaptation, Freedom, Sport, SAT, Love, Pain, NEWS

Adaptation: Adaptation is a feature length documentary film which follows a group of wheelchair athletes as they converge in British Columbia, Canada for the BC Summer Race Series.

Key Points: 
  • Adaptation: Adaptation is a feature length documentary film which follows a group of wheelchair athletes as they converge in British Columbia, Canada for the BC Summer Race Series.
  • The World’s first downhill mountain bike race series to include an adaptive mountain bike (aMTB) category.
  • However, Adaptation is not just a film about a race, it’s a group of stories about the human race and our ability to overcome adversity.
  • The BC Summer Series and mountain bike culture truly welcomed the adaptive athletes with open arms.”

Vivtex and AI Proteins Enter Strategic R&D Collaboration to Develop Novel, Oral Biologic Therapies for Inflammatory Diseases

Retrieved on: 
星期四, 一月 18, 2024
Patient, TNF, Biotechnology, AI, Protein, Inflammation, TNFR1, FDA, Therapy, Pharmaceutical industry

Vivtex Corporation (“Vivtex”), a biotech company aiming to transform the development of oral biologic therapies for major diseases, and AI Proteins, Inc., a growing biotechnology company that utilizes computational de novo protein design to create novel therapeutic miniproteins, today announced they have entered a strategic R&D collaboration to develop novel, oral biologic therapies for inflammatory diseases.

Key Points: 
  • Vivtex Corporation (“Vivtex”), a biotech company aiming to transform the development of oral biologic therapies for major diseases, and AI Proteins, Inc., a growing biotechnology company that utilizes computational de novo protein design to create novel therapeutic miniproteins, today announced they have entered a strategic R&D collaboration to develop novel, oral biologic therapies for inflammatory diseases.
  • Under the agreement, the companies will jointly conduct and share the costs of the program and will co-own any resulting data.
  • With current TNF-alpha pathway inhibitors being injectables, there is a major opportunity to develop oral anti-inflammatory medicines with differentiated best-in-class safety and efficacy.
  • This collaboration aims to combine promising features of our powerful miniprotein platform and Vivtex’s transformational oral biologics platform to develop anti-inflammatory therapeutics.”

Human medicines European public assessment report (EPAR): Libmyris, adalimumab, Date of authorisation: 12/11/2021, Revision: 2, Status: Authorised

Retrieved on: 
星期五, 一月 5, 2024
Marketing, INN, Axial spondyloarthritis, Tissue, Heart, Cancer, Inflammation, Red, Ankylosing spondylitis, Infection, Back pain, Anatomy, Ulcer, IIA, Skin, Hidradenitis suppurativa, Tuberculosis, Bone marrow, ATC, Joint, Hidradenitis, Pain, Psoriatic arthritis, Bleeding, Disease, Nose, Blood, Safety, Heart failure, Rheumatoid arthritis, Patient, Medical Subject Headings, Pediatrics, Immune system, Ulcerative colitis, International, HS, Lupus, Arthritis, Language, Mouth, Laboratory, Scar, Child, Select, Methotrexate, TNF, Axial, Headache, Swelling, Stevens–Johnson syndrome, European Medicines Agency, Spine, Abscess, Rash, Frankincense

Human medicines European public assessment report (EPAR): Libmyris, adalimumab, Date of authorisation: 12/11/2021, Revision: 2, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Libmyris, adalimumab, Date of authorisation: 12/11/2021, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Rixathon, rituximab, Date of authorisation: 15/06/2017, Revision: 13, Status: Authorised

Retrieved on: 
星期四, 一月 4, 2024
Marketing, BAL, PV, INN, Risk, MPA, Shivering, DLBCL, CD20, BLL, PML, Pemphigus vulgaris, Cancer, Inflammation, Infection, Anatomy, IIA, Skin, Chills, Fever, ATC, Joint, Bone marrow, GPA, Disease, Nose, Ageing, Allergy, Glucocorticoid, CLL, NHL, Safety, Rheumatoid arthritis, Patient, Medical Subject Headings, Cyclophosphamide, Immune system, Granuloma, Antibody, Vincristine, International, Arthritis, Language, Mouth, Follicular lymphoma, Microscopic polyangiitis, Select, Overview, B cell, Methotrexate, Prednisolone, TNF, CHOP, Blood, Vasculitis, Lymphocytosis, European Medicines Agency, Doxorubicin, Chronic lymphocytic leukemia, DMARD, Medical device

Human medicines European public assessment report (EPAR): Rixathon, rituximab, Date of authorisation: 15/06/2017, Revision: 13, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Rixathon, rituximab, Date of authorisation: 15/06/2017, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Truxima, rituximab, Date of authorisation: 17/02/2017, Revision: 21, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024
Marketing, INN, Risk, MPA, Shivering, CD20, PML, ACR20, Pemphigus vulgaris, Cancer, Inflammation, Death, Infection, Anatomy, IIA, Skin, Chills, Fever, ATC, Joint, Bone marrow, GPA, Disease, Pemphigus, Allergy, B cell, Hepatitis B virus, Glucocorticoid, NHL, CLL, Safety, Rheumatoid arthritis, Arthritis, Patient, Medical Subject Headings, Cyclophosphamide, Immune system, Granuloma, Antibody, Vincristine, International, Language, Blood, Mouth, Follicular lymphoma, Microscopic polyangiitis, Select, Methotrexate, Prednisolone, Autoimmune disease, TNF, CHOP, Vasculitis, European Medicines Agency, Doxorubicin, Cell, Chronic lymphocytic leukemia, Resuscitation, DMARD, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Truxima, rituximab, Date of authorisation: 17/02/2017, Revision: 21, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Truxima, rituximab, Date of authorisation: 17/02/2017, Revision: 21, Status: Authorised